Treatment of type 2 diabetes mellitus

Garth Cooper; J.S. Garth; [Unknown] Greene; [Unknown] Jr; [Unknown] Howard

Treatment of type 2 diabetes mellitus

Garth Cooper (Other), J.S. Garth (Other), [Unknown] Greene (Other), [Unknown] Jr (Other), [Unknown] Howard (Other)

Research output: Patent

Abstract

Antibody methods for blocking the effects of diabetes-associated peptide, or "amylin", a hormone found in the amyloid masses of Type 2 diabetics, are disclosed. This putative hormone has been discovered to function both to inhibit insulin secretion and to inhibit glycogen synthesis. Regulation is accomplished by blocking the binding of amylin or amylin agonists, including calcitonin gene related peptide (CGRP), or biologically active sub-peptides thereof. Inhibitors include antibodies directed to amylin and amylin agonist active sites. Other antagonists include anti-idiotype antibodies directed to antibodies directed to amylin.

Original language	English
Patent number	US5716619
Publication status	Published - 10 Feb 1998

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@misc{2b3656f5ad8e4108bd2fb6e8edce407d,

title = "Treatment of type 2 diabetes mellitus",

abstract = "Antibody methods for blocking the effects of diabetes-associated peptide, or {"}amylin{"}, a hormone found in the amyloid masses of Type 2 diabetics, are disclosed. This putative hormone has been discovered to function both to inhibit insulin secretion and to inhibit glycogen synthesis. Regulation is accomplished by blocking the binding of amylin or amylin agonists, including calcitonin gene related peptide (CGRP), or biologically active sub-peptides thereof. Inhibitors include antibodies directed to amylin and amylin agonist active sites. Other antagonists include anti-idiotype antibodies directed to antibodies directed to amylin.",

author = "Garth Cooper and J.S. Garth and [Unknown] Greene and [Unknown] Jr and [Unknown] Howard",

note = "Issuing organisation: USPLocation issued: USA; US5716619",

year = "1998",

month = feb,

day = "10",

language = "English",

type = "Patent",

}

TY - PAT

T1 - Treatment of type 2 diabetes mellitus

A2 - Cooper, Garth

A2 - Garth, J.S.

A2 - Greene, [Unknown]

A2 - Jr, [Unknown]

A2 - Howard, [Unknown]

N1 - Issuing organisation: USPLocation issued: USA

PY - 1998/2/10

Y1 - 1998/2/10

N2 - Antibody methods for blocking the effects of diabetes-associated peptide, or "amylin", a hormone found in the amyloid masses of Type 2 diabetics, are disclosed. This putative hormone has been discovered to function both to inhibit insulin secretion and to inhibit glycogen synthesis. Regulation is accomplished by blocking the binding of amylin or amylin agonists, including calcitonin gene related peptide (CGRP), or biologically active sub-peptides thereof. Inhibitors include antibodies directed to amylin and amylin agonist active sites. Other antagonists include anti-idiotype antibodies directed to antibodies directed to amylin.

AB - Antibody methods for blocking the effects of diabetes-associated peptide, or "amylin", a hormone found in the amyloid masses of Type 2 diabetics, are disclosed. This putative hormone has been discovered to function both to inhibit insulin secretion and to inhibit glycogen synthesis. Regulation is accomplished by blocking the binding of amylin or amylin agonists, including calcitonin gene related peptide (CGRP), or biologically active sub-peptides thereof. Inhibitors include antibodies directed to amylin and amylin agonist active sites. Other antagonists include anti-idiotype antibodies directed to antibodies directed to amylin.

M3 - Patent

M1 - US5716619

ER -

Treatment of type 2 diabetes mellitus

Abstract

UN SDGs

Fingerprint

Cite this